Reduced-Dose JAK Inhibitors Maintain Persistence in Low-Risk Rheumatoid Arthritis

Dosing Strategies and Treatment Persistence in Rheumatoid Arthritis

Janus kinase inhibitors have expanded the therapeutic landscape for moderate to severe rheumatoid arthritis, offering efficacy comparable to biological disease-modifying antirheumatic drugs [1]. While these agents significantly improve patient-reported outcomes and disease activity, clinical adoption is often tempered by concerns regarding dose-dependent adverse events, particularly venous thromboembolism and serious infections [2, 3]. Current evidence suggests that while higher doses do not always provide incremental clinical benefits, they may increase the risk of specific cardiovascular complications [4]. Consequently, many clinicians explore dose reduction strategies in stable patients to balance long-term safety with the maintenance of clinical remission [5]. To guide these everyday prescribing decisions, a new multicenter registry study examines how initial dosing strategies influence long-term drug retention, a key marker of both efficacy and tolerability, across different patient risk profiles.

Registry Analysis of Dosing Strategies

The researchers conducted a multicenter observational study utilizing a Japanese real-world registry to evaluate the long-term outcomes of Janus kinase inhibitor therapy. The total study population included 1,135 patients with rheumatoid arthritis who initiated treatment with these agents between 2013 and 2025. To understand the impact of initial management choices on treatment longevity, the investigators classified patients according to their initial dosing strategy, distinguishing between those started on standard doses and those receiving reduced doses from the outset. A critical component of the analysis involved restricting the primary inference to patients with preserved renal function. In this specific subgroup, prescribing a reduced dose reflects discretionary clinical decision-making by the physician rather than a mandatory adjustment necessitated by impaired drug clearance. To ensure a rigorous comparison between the two dosing groups, the authors employed propensity score matching (a statistical technique that balances baseline patient characteristics across treatment arms to mimic a randomized trial). This method allowed the researchers to adjust for confounding by indication, ensuring that the standard and reduced-dose cohorts were clinically comparable at the start of the observation period despite the observational nature of the registry data.

Comparable Retention and Disease Control

The study evaluated the long-term viability of treatment by comparing 24-month drug retention between standard-dose and reduced-dose Janus kinase inhibitors. To track treatment discontinuation over time, the researchers utilized Kaplan-Meier analyses (a method to estimate the probability of patients remaining on therapy over a specific period) and Cox proportional hazards models (a statistical technique to assess how different patient variables influence the risk of stopping the medication). Among the matched cohort of patients with preserved renal function, the analysis demonstrated that 24-month drug retention was comparable between those initiated on standard doses and those receiving reduced doses. This finding reassures clinicians that for patients without renal impairment, starting at a lower dose does not inherently result in a higher rate of treatment failure or earlier discontinuation. Clinical outcomes beyond treatment persistence also showed no significant disadvantage for the lower-dose strategy. Disease activity improved similarly in both the standard-dose and reduced-dose groups, suggesting that the initial reduction in dosage did not compromise the achievement of therapeutic targets. Furthermore, the researchers found that glucocorticoid use remained low in both cohorts throughout the study period. Crucially, there was no compensatory escalation of glucocorticoids in the reduced-dose group. This signifies that physicians did not need to rely on supplemental steroid therapy to rescue disease control when using lower doses of Janus kinase inhibitors, confirming that reduced-dose initiation can maintain both efficacy and treatment longevity in appropriately selected patients.

Risk Stratification and Renal Considerations

To identify which patient subgroups are best suited for dose reduction, the researchers examined whether poor prognostic factor burden and renal function modified treatment persistence. These analyses were prespecified and stratified by poor prognostic factor burden, which the authors categorized as 0-2 versus 3-4 factors (clinical markers that typically include high disease activity, the presence of autoantibodies, or early joint erosions). For patients with a low poor prognostic factor burden (0-2 factors), the study found that reduced dosing showed comparable performance to standard dosing in terms of 24-month drug retention. This indicates that in patients with fewer baseline risk markers, a lower initial dose of a Janus kinase inhibitor is a viable long-term strategy that does not increase the risk of treatment failure. Conversely, standard-dose initiation showed more favorable persistence in patients with multiple poor prognostic factors (3-4 factors). In this higher-risk cohort, the full therapeutic dose appears necessary to maintain treatment continuity over the two-year study period. The researchers also conducted supportive analyses in patients with reduced renal function, a population that frequently requires dose adjustments based on altered drug clearance. Interestingly, among these patients, standard dosing was associated with higher drug retention compared to reduced dosing. This suggests that even when renal function is impaired, clinicians must carefully balance the risk of drug accumulation against the risk of inadequate disease control, as under-dosing may lead to earlier treatment discontinuation due to inefficacy. The authors noted that findings in poor prognostic factor-stratified analyses and in patients with reduced renal function should be interpreted cautiously and warrant further investigation. Ultimately, these nuances emphasize that while dose reduction is highly effective for many patients with preserved renal function, the presence of multiple prognostic risk factors or renal impairment may necessitate a standard initial dosing strategy to ensure long-term treatment success.

References

1. Cai W, Tong R, Sun Y, Yao Y, Zhang J. Comparative efficacy of five approved Janus kinase inhibitors as monotherapy and combination therapy in patients with moderate-to-severe active rheumatoid arthritis: a systematic review and network meta-analysis of randomized controlled trials.. Frontiers in pharmacology. 2024. doi:10.3389/fphar.2024.1387585

2. Xie W, Huang Y, Xiao S, Sun X, Fan Y, Zhang Z. Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials.. Annals of the rheumatic diseases. 2019. doi:10.1136/annrheumdis-2018-214846

3. Ioannidis DC, Kapasouri EM, Vassiliou VS, Ntatsaki E. Cardiovascular and Thromboembolic Risk of Janus Kinase Inhibitors Compared to Other Disease-Modifying Drugs in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.. Journal of personalized medicine. 2026. doi:10.3390/jpm16020113

4. Weng C, Xue L, Wang Q, Lu W, Xu J, Liu Z. Comparative efficacy and safety of Janus kinase inhibitors and biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and network meta-analysis.. Therapeutic advances in musculoskeletal disease. 2021. doi:10.1177/1759720X21999564

5. Álvaro JMÁ, Fontecha PDDC, Sánchez JLA, et al. Update of the Consensus Statement of the Spanish Society of Rheumatology on the use of biological and synthetic targeted therapies in rheumatoid arthritis.. Reumatologia clinica. 2024. doi:10.1016/j.reumae.2024.09.002